Dark Classics in Chemical Neuroscience: Mescaline
This review (2018) looks at the history, pharmacology, metabolism, and psychological effects of mescaline.
Authors
- Cassels, B. K.
- Sáez-Briones, P.
Published
Abstract
Archeological studies in the United States, Mexico, and Peru suggest that mescaline, as a cactus constituent, has been used for more than 6000 years. Although it is a widespread cactus alkaloid, it is present in high concentrations in few species, notably the North American peyote (Lophophora williamsii) and the South American wachuma (Trichocereus pachanoi, T. peruvianus, and T. bridgesii). Spanish 16th century chroniclers considered these cacti “diabolic”, leading to their prohibition, but their use persisted to our days and has been spreading for the last 150 years. In the late 1800s, peyote attracted scientific attention; mescaline was isolated, and its role in the psychedelic effects of peyote tops or “mescal buttons” was demonstrated. Its structure was established by synthesis in 1929, and alternative routes were developed, providing larger amounts for pharmacological and biosynthetic research. Although its effects are attributed mainly to its action as a 5-HT2A serotonin receptor agonist, mescaline binds in a similar concentration range to 5-HT1A and α2A receptors. It is largely excreted unchanged in human urine, and its metabolic products are apparently unrelated to its psychedelic properties. Its low potency is probably responsible for its relative neglect by recreational substance users, as the successful search for structure-activity relationships in the hallucinogen field focused largely on finding more potent analogues. Renewed interest in the possible therapeutic applications of psychedelic drugs may hopefully lead to novel insights regarding the commonalities and differences between the actions of individual classic hallucinogens.
Research Summary of 'Dark Classics in Chemical Neuroscience: Mescaline'
Introduction
Mescaline is one of the classic serotonergic psychedelics with an exceptionally long record of human use. Archaeological and ethnohistorical evidence indicates ingestion of mescaline-containing cacti for millennia: dried peyote tops (Lophophora williamsii) were radiocarbon-dated to about 5,800–6,000 years before present, a Trichocereus peruvianus spine cluster associated with artefacts dated to 6,200–6,800 YBP, and depictions of San Pedro (T. pachanoi) appear from at least 2,500 YBP. Despite this deep cultural history, contemporary use of isolated mescaline appears limited, probably because full psychedelic effects require relatively large oral doses (around 300 mg of the free base), whereas ingestion of peyote buttons or San Pedro brews remains common in some ceremonial and recreational contexts and has spread geographically over the last 150 years. This review sets out to synthesise knowledge on mescaline’s occurrence, chemistry, synthesis, biosynthesis, pharmacology, metabolism and structure–activity relationships (SAR). The authors survey historical reports, botanical and chemical analyses, early and mid-20th century human and animal pharmacology, and the development of mescaline analogues, identifying gaps in recent research and areas where renewed study might be productive for both basic neuroscience and potential therapeutic applications.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Cassels, B. K., & Sáez-Briones, P. (2018). Dark Classics in Chemical Neuroscience: Mescaline. ACS Chemical Neuroscience, 9(10), 2448-2458. https://doi.org/10.1021/acschemneuro.8b00215
References (17)
Papers cited by this study that are also in Blossom
Liechti, M. E. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Forstmann, M., Sagioglou, C. · Journal of Psychopharmacology (2017)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)
Show all 17 referencesShow fewer
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
González, D., Torrens, M., Farré, M. · BioMed Research International (2015)
Souza, D. C. D., Pérez, C., Papaseit, E. et al. · Frontiers in Pharmacology (2018)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Cited By (7)
Papers in Blossom that reference this study
Mueller, L., Klaiber, A., Ley, L. et al. · Clinical Pharmacokinetics (2025)
Mueller, J., Mueller, M. J., Aicher, H. D. et al. · International Journal of Neuropsychopharmacology (2025)
Klaiber, A., Humbert‐Droz, M., Ley, L. et al. · British Journal of Clinical Pharmacology (2024)
Klaiber, A., Schmid, Y., Becker, A. M. et al. · Translational Psychiatry (2024)
Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)
Narine, K., Campbell, I., Dyck, J. et al. · Neuropharmacology (2022)
James Perez Custodio, R., Ortiz, D. M., Lee, H. J. et al. · SSRN (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.